<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03170050</url>
  </required_header>
  <id_info>
    <org_study_id>YYP-YYD701_001</org_study_id>
    <nct_id>NCT03170050</nct_id>
  </id_info>
  <brief_title>Clinical Trial of YYD701-2 for Treatment of Nasolabial Folds</brief_title>
  <official_title>A Multicenter, Active-controlled, Randomized, Evaluator and Subject Blinded, Split-face, Comparative, Non-inferiority and Confirmatory Clinical Study of the Efficacy and Safety Between YYD701-2 and Restylane Perlane Lidocaine for Temporary Correction of Moderate to Severe Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yooyoung Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yooyoung Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, active-controlled, randomized, evaluator and subject blinded, split-face,
      comparative, non-inferiority, Medical device Clinical trial.

      This study is randomized, evaluator and subject blinded, split-face medical device Clinical
      trial. The Subjects are injected investigational device(YYD701-2 or Restylane Perlane
      Lidocaine) in right or left nasolabial folds.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">November 21, 2017</completion_date>
  <primary_completion_date type="Actual">November 21, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The Subjects are injected investigational devide(YYD701-2 or Restylane Perlane Lidocaine) in right or left nasolabial folds</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in Wrinkle Severity Rating Scale (WSRS) as evaluated by independent evaluator through Photographs.</measure>
    <time_frame>from baseline to 24 weeks</time_frame>
    <description>Score of WSRS assessed by the independent evaluator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in Wrinkle Severity Rating Scale (WSRS) as evaluated by independent evaluator through Photographs.</measure>
    <time_frame>from baseline to 2, 8, 16 weeks</time_frame>
    <description>Score of WSRS assessed by the independent evaluator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Wrinkle Severity Rating Scale (WSRS) as evaluated by investigator.</measure>
    <time_frame>from baseline to 2, 8, 16, 24 weeks</time_frame>
    <description>Score of WSRS assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a ≥ 1 point on Global Aesthetic Improvement Scale as evaluated by an investigator</measure>
    <time_frame>2, 8, 16, 24 weeks after week 0 (injection date)</time_frame>
    <description>Score of GAIS assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a ≥ 1 point on Global Aesthetic Improvement Scale as evaluated by a subject</measure>
    <time_frame>2, 8, 16, 24 weeks after week 0 (injection date)</time_frame>
    <description>Score of GAIS assessed by subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a ≥ 1 point change on Wrinkle Severity Rating Scale as evaluated by independent evaluator through Photographs.</measure>
    <time_frame>from baseline to 2, 8, 16, 24 weeks</time_frame>
    <description>Score of WSRS assessed by the independent evaluator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a ≥ 1 point change on Wrinkle Severity Rating Scale as evaluated by the investigator</measure>
    <time_frame>from baseline to 2, 8, 16, 24 weeks</time_frame>
    <description>Score of WSRS assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale as evaluated by a subject</measure>
    <time_frame>week 0 (injection date)</time_frame>
    <description>Score of VAS assessed by subject</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">107</enrollment>
  <condition>Wrinkle Severity Rating Scale(WSRS) Grade 3 (Moderate) or 4 (Severe) of Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>YYD701-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YYD701-2 Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restylane Perlane Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Restylane Perlane Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YYD701-2</intervention_name>
    <description>HA Filler</description>
    <arm_group_label>YYD701-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Perlane Lidocaine</intervention_name>
    <description>HA Filler</description>
    <arm_group_label>Restylane Perlane Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and Female aged between 30 and 75 years, inclusive

          -  Subjects who want improvement of nasolabial folds that are rated as grade 3 or 4 on
             Wrinkle severity rating scale(WSRS)

          -  Subjects who have visually symmetrical bilateral nasolabial folds

          -  Subjects who consent to discontinue all dermatological treatment or cure including
             wrinkle correction in and around infraorbital region during this trial

          -  Subjects who voluntarily decide to participate in this trial and provide written
             consent in the Informed Consent Form

        Exclusion Criteria:

          -  Subject who have bleeding disorder in the past or present

          -  Other criteria as identified in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chung-Ang Univ. Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

